DMK Pharmaceuticals Corporation
DMKPQ · OTC
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Revenue | $9 | $7 | $1,453 | $2,151 |
| % Growth | 30.5% | -99.5% | -32.4% | – |
| Cost of Goods Sold | $341 | $442 | $1,891 | $2,849 |
| Gross Profit | -$332 | -$435 | -$438 | -$698 |
| % Margin | -3,658.8% | -6,263.4% | -30.1% | -32.5% |
| R&D Expenses | $419 | $377 | $1,311 | $860 |
| G&A Expenses | $0 | $4,033 | $0 | $0 |
| SG&A Expenses | $2,515 | $3,953 | $4,679 | $2,784 |
| Sales & Mktg Exp. | $0 | -$81 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2,934 | $4,329 | $5,990 | $3,644 |
| Operating Income | -$3,265 | -$4,764 | -$6,428 | -$4,342 |
| % Margin | -36,030.7% | -68,603.2% | -442.4% | -201.9% |
| Other Income/Exp. Net | $1,529 | -$2,239 | -$2,587 | $941 |
| Pre-Tax Income | -$1,736 | -$7,003 | -$9,015 | -$3,401 |
| Tax Expense | $0 | $0 | $0 | $2 |
| Net Income | -$1,388 | -$8,574 | -$8,943 | -$3,328 |
| % Margin | -15,317.2% | -123,457.5% | -615.5% | -154.7% |
| EPS | -0.2 | -3.34 | -4.09 | -1.55 |
| % Growth | 94% | 18.3% | -163.9% | – |
| EPS Diluted | -0.2 | -3.34 | -4.09 | -1.55 |
| Weighted Avg Shares Out | 7,066 | 2,569 | 2,185 | 2,143 |
| Weighted Avg Shares Out Dil | 7,066 | 2,569 | 2,185 | 2,143 |
| Supplemental Information | – | – | – | – |
| Interest Income | $14 | $1 | $0 | $44 |
| Interest Expense | $29 | $46 | $0 | -$379 |
| Depreciation & Amortization | $2 | $81 | $103 | $367 |
| EBITDA | -$1,705 | -$6,877 | -$6,318 | -$3,034 |
| % Margin | -18,811% | -99,014.1% | -434.8% | -141.1% |